Literature DB >> 10889358

Vaccination of mice against schistosoma bovis with a recombinant fatty acid binding protein from Fasciola hepatica.

J L Abáné1, A Oleaga, V Ramajo, P Casanueva, J L Arellano, G V Hillyer, A Muro.   

Abstract

Two strains of mice (NMRI and C57/BL) were each immunized with a 15kDa recombinant Fasciola hepatica fatty acid binding protein (FABP) (Fh15) and challenged percutaneously with Schistosoma bovis cercariae. C57/BL mice immunized with Fh15 had significant reductions in S. bovis worm burden recoveries (72% reductions over controls). When using NMRI mice, Fh15 in Freund's adjuvant failed to induce significant protection against S. bovis. In C57/BL mice, only antibodies to the IgG2a isotype increased after the second immunization and remained high through 8 weeks of S. bovis infection. This is the first time that a heterologous recombinant molecule from F. hepatica has been used in vaccination against S. bovis, obtaining a significant reduction in the number of worms in C57/BL mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10889358     DOI: 10.1016/s0304-4017(00)00263-6

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  7 in total

1.  Biochemical characterization and differential expression of a 16.5-kilodalton tegument-associated antigen from the liver fluke Fasciola hepatica.

Authors:  José F Gaudier; Kimberly Cabán-Hernández; Antonio Osuna; Ana M Espino
Journal:  Clin Vaccine Immunol       Date:  2012-01-25

2.  Preliminary protective capacity study of a Dicrocoelium dendriticum antigenic protein in hamsters.

Authors:  C González-Lanza; M Y Manga-González; B Revilla-Nuín
Journal:  Parasitol Res       Date:  2006-11       Impact factor: 2.289

3.  Human secretory immune response to fatty acid-binding protein fraction from Giardia lamblia.

Authors:  S M T Hasan; M Maachee; O M Córdova; R Diaz de la Guardia; M Martins; A Osuna
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

4.  Excretory/secretory proteome of the adult developmental stage of human blood fluke, Schistosoma japonicum.

Authors:  Feng Liu; Shu-Jian Cui; Wei Hu; Zheng Feng; Zhi-Qin Wang; Ze-Guang Han
Journal:  Mol Cell Proteomics       Date:  2009-03-18       Impact factor: 5.911

Review 5.  Schistosome Vaccine Adjuvants in Preclinical and Clinical Research.

Authors:  Rachel Stephenson; Hong You; Donald P McManus; Istvan Toth
Journal:  Vaccines (Basel)       Date:  2014-09-02

6.  Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems.

Authors:  Belén Vicente; Julio López-Abán; Jose Rojas-Caraballo; Esther del Olmo; Pedro Fernández-Soto; Antonio Muro
Journal:  Parasit Vectors       Date:  2016-04-18       Impact factor: 3.876

Review 7.  Do schistosome vaccine trials in mice have an intrinsic flaw that generates spurious protection data?

Authors:  R Alan Wilson; Xiao-Hong Li; William Castro-Borges
Journal:  Parasit Vectors       Date:  2016-02-17       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.